Trial
NCT00484601
Ifosfamide and Doxorubicin in Patients With Refractory Nasopharyngeal Carcinoma
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Collaborators
—
Condition
Refractory Nasopharyngeal Carcinoma
Intervention
Ifosfamide
Why stopped
Low accrual.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2019-02-11